pubmed.ncbi.nlm.nih.gov

BCG immunotherapy of lung cancer - PubMed

PMID: 7373947
DOI: 10.1007/BF02468640

BCG immunotherapy of lung cancer

E C Holmes. Jpn J Surg. 1980 Mar.

Abstract

Thirty-three patients have undergone BCG intralesional injection into pulmonary tumors. Six received the injection by way of the bronchoscope and 27 were injected percutaneously under fluoroscopic control. The toxicity of this treatment is closely related to PPD reactivity. PPD-negative patients have little fever and malaise. However patients with strongly positive PPD reactions have extensive and prolonged fever. Twenty-six of the 27 patients injected with BCG underwent pulmonary resection. There were no significant postoperative complications. Histologically BCG induces a granulomatous inflammatory reaction, and in the patients who are PPD-positive there is extensive plasma-cell infiltration and de novo germinal center formation within the tumor. Eighty-five percent of the patients with bronchogenic carcinoma and 58 percent of the patients with metastatic cancer are alive and well at a median follow-up of 16 months following pulmonary resection.

PubMed Disclaimer

Cited by

Bronchoscopic intratumoural therapies for non-small cell lung cancer.
DeMaio A, Sterman D. DeMaio A, et al. Eur Respir Rev. 2020 Jun 16;29(156):200028. doi: 10.1183/16000617.0028-2020. Print 2020 Jun 30. Eur Respir Rev. 2020. PMID: 32554757 Free PMC article. Review.

References

1. Semin Oncol. 1974 Dec;1(4):337-50 - PubMed
1. Ann Surg. 1974 Oct;180(4):635-43 - PubMed
1. Semin Oncol. 1974 Dec;1(4):319-35 - PubMed
1. J Thorac Cardiovasc Surg. 1976 Feb;71(2):161-8 - PubMed
1. Gan. 1976 Dec;67(6):787-95 - PubMed

MeSH terms

Substances

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

BCG immunotherapy of lung cancer - PubMed